• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    9/26/24 4:05:52 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    SC 13G 1 g084448_sc13g.htm SC 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.   )*

     

    Scorpius Holdings, Inc.

     

     (Name of Issuer)

     

    Common Stock, $0.0002 par value per share

     

     (Title of Class of Securities)

     

    42237K508

     

     (CUSIP Number)

     

    September 17, 2024

     

     (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 42237K508   13G   Page 2 of 8 Pages
       
    1.

    NAMES OF REPORTING PERSONS

     

    3i, LP 

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    359,297 (1)  

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    359,297 (1)  

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    359,297 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9% (1) 

    12. TYPE OF REPORTING PERSON (see instructions)

    PN

     

    (1)  As more fully described in Item 4 of this statement on Schedule 13G (this “Schedule 13G”), such shares and percentage are based on 3,384,268 shares of common stock, par value $0.0002 per share, of the issuer (the “Common Stock”) outstanding, as verified with the issuer, and do not give full effect to the shares of Common Stock issuable upon full exercise of the (i) common stock purchase warrants of the issuer (the “Warrants”) directly owned by the reporting person, which exercise is subject to a 4.99% beneficial ownership limitation provision, and (ii) pre-funded common stock purchase warrants of the issuer (the “Pre-Funded Warrants”) directly owned by the reporting person, which exercise is subject to a 9.99% beneficial ownership limitation provision.

     

     

    CUSIP No. 42237K508   13G   Page 3 of 8 Pages
       
    1.

    NAMES OF REPORTING PERSONS

     

    3i Management LLC 

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    359,297 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    359,297 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    359,297 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

    (1)  As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 3,384,268 shares of Common Stock outstanding, as verified with the issuer, and do not give full effect to the (i) Warrants indirectly owned by the reporting person, which exercise is subject to a 4.99% beneficial ownership limitation provision, and (ii) Pre-Funded Warrants indirectly owned by the reporting person, which exercise is subject to a 9.99% beneficial ownership limitation provision.

     

     

    CUSIP No. 42237K508   13G   Page 4 of 8 Pages
       
    1. NAMES OF REPORTING PERSONS

    Maier Joshua Tarlow
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☒
    (b)    ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER

     

    359,297 (1) 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER

     

    359,297 (1) 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    359,297 (1) 

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% (1)
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    (1)   As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 3,384,268 shares of Common Stock outstanding, as verified with the issuer, and do not give full effect to the (i) Warrants indirectly owned by the reporting person, which exercise is subject to a 4.99% beneficial ownership limitation provision, and (ii) Pre-Funded Warrants indirectly owned by the reporting person, which exercise is subject to a 9.99% beneficial ownership limitation provision.

     

     

    CUSIP No. 42237K508   13G   Page 5 of 8 Pages

     

    Item 1(a). Name of Issuer:

     

    Scorpius Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive offices are located at 627 Davis Drive, Suite 300, Morrisville, North Carolina, 27560.

     

    Item 2(a). Names of Persons Filing:

     

    This Statement on Schedule 13G (the “Schedule 13G”) is filed by:
     
    (i) 3i, LP, a Delaware limited partnership (“3i”);
     
    (ii) 3i Management LLC, a Delaware limited liability company (“3i Management”); and
     
    (iii)  Maier Joshua Tarlow (“Mr. Tarlow”).

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which they have agreed to file this Schedule 13G and all subsequent amendments jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.  

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is 2 Wooster Street, 2nd Floor, New York, NY 10013.

     

    Item 2(c). Citizenship:

     

    3i is a Delaware limited partnership. 3i Management is a Delaware limited liability company. Mr. Tarlow is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities:

     

    The title of the class of securities to which this statement relates is the Issuer’s shares of common stock, $0.0002 par value per share (the “Common Stock”).

     

    Item 2(e). CUSIP Number: 42237K508

     

     

    CUSIP No. 42237K508   13G   Page 6 of 8 Pages

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 3,384,268 shares of Common Stock outstanding, as verified with the Issuer, and (ii) 212,305 shares of Common Stock issuable upon exercise of the Issuer’s pre-funded common stock purchase warrants held by the Reporting Persons, which are exercisable for up to 9,727,000 shares of Common Stock (the “Pre-Funded Warrants”), but are subject to a 9.99% beneficial ownership limitation provision.

     

    As of September 26, 2024, the Reporting Persons hold (i) 146,992 shares of Common Stock, (ii) Pre-Funded Warrants exercisable for up to 9,727,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation provision, and (ii) common stock purchase warrants of the Issuer exercisable for up to 150,000 shares of Common Stock (the “Warrants”), subject to a 4.99% beneficial ownership limitation provision. Due to the interaction between the beneficial ownership limitation provisions in each of the Pre-Funded Warrants and the Warrants, 3i is prohibited from exercising the Warrants for shares of Common Stock if, as a result of such exercise, 3i, together with its affiliates and any persons acting as a group together with 3i or any of such affiliates, would beneficially own more than 4.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. As a result of 3i’s beneficial ownership of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants up to the 9.99% beneficial ownership limitation provision included therein, 3i cannot exercise the Warrants and can only exercise the Pre-Funded Warrants for up to 212,305 shares of Common Stock.

     

    Consequently, 3i is the beneficial owner of 359,297 shares of Common Stock (the “Shares”). 3i has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr. Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr. Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed to beneficially own the Shares beneficially owned by 3i.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.  

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    See Exhibit 1 filed herewith.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

      

    Item 10. Certification.

     

    By signing below each of the Reporting Persons certify that, to the best of each of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.  

     

     

    CUSIP No. 42237K508   13G   Page 7 of 8 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 26, 2024 3i, LP
         
      By: 3i Management LLC,
        its General Partner
         
      By: /s/ Maier J. Tarlow
        Name: Maier J. Tarlow
        Title: Manager
         
      3i Management LLC
         
      By: /s/ Maier J. Tarlow
        Name: Maier J. Tarlow
        Title: Manager
         
      /s/ Maier J. Tarlow
     

    Maier J. Tarlow

     

     

    CUSIP No. 42237K508   13G   Page 8 of 8 Pages

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

     

    Date: September 26, 2024 3i, LP
         
      By: 3i Management LLC,
             its General Partner
         
      By: /s/ Maier J. Tarlow
        Name: Maier J. Tarlow
        Title: Manager
         
      3i Management LLC
         
      By: /s/ Maier J. Tarlow
        Name: Maier J. Tarlow
        Title: Manager
         
      /s/ Maier J. Tarlow
      Maier J. Tarlow

     

    Get the next $SCPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

      5/14/25 8:30:00 AM ET
      $SCPX
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

      SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

      4/30/25 4:05:30 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

      DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

      11/14/24 4:15:00 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

      DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

      10/2/24 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    SEC Filings

    See more
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      6/3/25 4:30:27 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/20/25 5:07:29 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Scorpius Holdings Inc.

      NT 10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/15/25 5:24:59 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Thuan Tan Sze

      3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      3/12/25 4:07:02 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

      4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      5/17/24 4:30:21 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/26/24 4:05:52 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/6/24 4:01:41 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

      SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

      5/21/24 5:25:39 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care